These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36800517)

  • 1. Risk Severity Model for Pediatric Autosomal Dominant Polycystic Kidney Disease Using 3D Ultrasound Volumetry.
    Breysem L; De Keyzer F; Schellekens P; Dachy A; De Rechter S; Janssens P; Vennekens R; Bammens B; Irazabal MV; Van Ongeval C; Harris PC; Mekahli D;
    Clin J Am Soc Nephrol; 2023 Feb; 18(5):581-91. PubMed ID: 36800517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging based kidney volume assessment for risk stratification in pediatric autosomal dominant polycystic kidney disease.
    Yilmaz K; Saygili S; Canpolat N; Akgun-Dogan O; Yuruk Yildirim ZN; Cicek-Oksuz RY; Oner HA; Aksu B; Akyel NG; Oguzhan-Hamis O; Dursun H; Yavuz S; Cicek N; Akinci N; Karabag Yilmaz E; Agbas A; Nayir AN; Konukoglu D; Kurugoglu S; Sever L; Caliskan S
    Front Pediatr; 2024; 12():1357365. PubMed ID: 38464892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
    Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
    Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.
    Bhutani H; Smith V; Rahbari-Oskoui F; Mittal A; Grantham JJ; Torres VE; Mrug M; Bae KT; Wu Z; Ge Y; Landslittel D; Gibbs P; O'Neill WC; Chapman AB;
    Kidney Int; 2015 Jul; 88(1):146-51. PubMed ID: 25830764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total Kidney Volume Measurements in ADPKD by 3D and Ellipsoid Ultrasound in Comparison with Magnetic Resonance Imaging.
    Akbari P; Nasri F; Deng SX; Khowaja S; Lee SH; Warnica W; Lu H; Rattansingh A; Atri M; Khalili K; York P
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):827-834. PubMed ID: 35383043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Patients with End-Stage Kidney Disease in ADPKD.
    Shukoor SS; Vaughan LE; Edwards ME; Lavu S; Kline TL; Senum SR; Mkhaimer Y; Zaatari G; Irazabal MV; Neal R; Hogan MC; Zoghby ZM; Harris PC; Torres VE; Chebib FT
    Kidney Int Rep; 2021 Mar; 6(3):755-767. PubMed ID: 33732990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with Protein-Truncating
    Lanktree MB; Guiard E; Akbari P; Pourafkari M; Iliuta IA; Ahmed S; Haghighi A; He N; Song X; Paterson AD; Khalili K; Pei YPC
    Clin J Am Soc Nephrol; 2021 Mar; 16(3):374-383. PubMed ID: 33602752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.
    Heyer CM; Sundsbak JL; Abebe KZ; Chapman AB; Torres VE; Grantham JJ; Bae KT; Schrier RW; Perrone RD; Braun WE; Steinman TI; Mrug M; Yu AS; Brosnahan G; Hopp K; Irazabal MV; Bennett WM; Flessner MF; Moore CG; Landsittel D; Harris PC;
    J Am Soc Nephrol; 2016 Sep; 27(9):2872-84. PubMed ID: 26823553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
    Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
    JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.
    Lavu S; Vaughan LE; Senum SR; Kline TL; Chapman AB; Perrone RD; Mrug M; Braun WE; Steinman TI; Rahbari-Oskoui FF; Brosnahan GM; Bae KT; Landsittel D; Chebib FT; Yu AS; Torres VE; ; Harris PC
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
    BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.
    Oberdhan D; Yarlas A; Bjorner JB; Krasa H
    Kidney Med; 2024 Jan; 6(1):100755. PubMed ID: 38192435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A; Lu Y; Kawano H; Horie S; Muto S
    Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
    Kistler AD; Serra AL; Siwy J; Poster D; Krauer F; Torres VE; Mrug M; Grantham JJ; Bae KT; Bost JE; Mullen W; Wüthrich RP; Mischak H; Chapman AB
    PLoS One; 2013; 8(1):e53016. PubMed ID: 23326375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
    Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.
    Bae KT; Shi T; Tao C; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE; Srivastava A; Irazabal MV; Abebe KZ; Harris PC; Landsittel DP;
    J Am Soc Nephrol; 2020 Jul; 31(7):1640-1651. PubMed ID: 32487558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exome sequencing of Saudi Arabian patients with ADPKD.
    Al-Muhanna FA; Al-Rubaish AM; Vatte C; Mohiuddin SS; Cyrus C; Ahmad A; Shakil Akhtar M; Albezra MA; Alali RA; Almuhanna AF; Huang K; Wang L; Al-Kuwaiti F; Elsalamouni TSA; Al Hwiesh A; Huang X; Keating B; Li J; Lanktree MB; Al-Ali AK
    Ren Fail; 2019 Nov; 41(1):842-849. PubMed ID: 31488014
    [No Abstract]   [Full Text] [Related]  

  • 18. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
    Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel three-dimensional imaging volumetry in autosomal dominant polycystic kidney disease: comparison with 2D volumetry.
    Shin D; Lee KB; Hyun YY; Lee YR; Hwang YH; Park HC; Ahn C
    Clin Nephrol; 2014 Aug; 82(2):98-106. PubMed ID: 25029513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients.
    Girardat-Rotar L; Braun J; Puhan MA; Abraham AG; Serra AL
    BMC Nephrol; 2017 Jul; 18(1):241. PubMed ID: 28716055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.